Why Cardiol Therapeutics Stock Is Still in Focus While Nasdaq Is Closed
Cardiol Therapeutics’ Toronto-listed shares rose 1.1% to C$1.84 on Monday, with light trading, as U.S. markets closed for Memorial Day. The company’s Phase III MAVERIC trial in recurrent pericarditis neared full enrollment, with 75% reached by April. Cardiol reported C$27.7 million in cash at March 31 and a first-quarter net loss of C$10.8 million. Management expects current cash to last into Q4 2027.